ACTONEL WITH CALCIUM (COPACKAGED) Drug Patent Profile
✉ Email this page to a colleague
When do Actonel With Calcium (copackaged) patents expire, and when can generic versions of Actonel With Calcium (copackaged) launch?
Actonel With Calcium (copackaged) is a drug marketed by Warner Chilcott and is included in one NDA.
The generic ingredient in ACTONEL WITH CALCIUM (COPACKAGED) is calcium carbonate; risedronate sodium. There are two hundred and eighty-two drug master file entries for this compound. Additional details are available on the calcium carbonate; risedronate sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ACTONEL WITH CALCIUM (COPACKAGED)?
- What are the global sales for ACTONEL WITH CALCIUM (COPACKAGED)?
- What is Average Wholesale Price for ACTONEL WITH CALCIUM (COPACKAGED)?
Summary for ACTONEL WITH CALCIUM (COPACKAGED)
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| DailyMed Link: | ACTONEL WITH CALCIUM (COPACKAGED) at DailyMed |
-patent-expirations.png "ACTONEL WITH CALCIUM (COPACKAGED) drug patent expirations")
US Patents and Regulatory Information for ACTONEL WITH CALCIUM (COPACKAGED)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Warner Chilcott | ACTONEL WITH CALCIUM (COPACKAGED) | calcium carbonate; risedronate sodium | TABLET;ORAL | 021823-001 | Aug 12, 2005 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ACTONEL WITH CALCIUM (COPACKAGED)
See the table below for patents covering ACTONEL WITH CALCIUM (COPACKAGED) around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 61370 | ⤷ Start Trial | |
| Australia | 5153485 | ⤷ Start Trial | |
| Australia | 587001 | ⤷ Start Trial | |
| Canada | 1320727 | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DIPHOSPHONATES GEMINAUX (PHARMACEUTICAL COMPOSITIONS CONTAINING GEMINAL DIPHOSPHONATES) | ⤷ Start Trial |
| Germany | 10075030 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ACTONEL WITH CALCIUM (COPACKAGED)
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0247633 | 62/1997 | Austria | ⤷ Start Trial | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
| 0186405 | SPC/GB00/021 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316 |
| 0186405 | C300031 | Netherlands | ⤷ Start Trial | PRODUCT NAME: RISEDRONINEZUUR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF FARMACEUTISCH AANVAARDBARE ESTER, IN HET BIJZONDER NATRIUMRISEDRONAAT; NAT REGISTRATION NO/DATE: RVG 24990 20000609; FIRST REGISTRATION: SE 15290 - 15297 19991007 |
| 0186405 | 2000C/028 | Belgium | ⤷ Start Trial | PRODUCT NAME: NATRIUMRISEDRONAAT; NAT. REGISTRATION NO/DATE: 354 IS 498 F3 20000508; FIRST REGISTRATION: SE 15290 19991007 |
| 0998292 | CA 2006 00005 | Denmark | ⤷ Start Trial | PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, COLECALCIFEROL |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch